In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.
Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.
What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?
In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
There is a lot of talk about biosimilar drugs. What makes a drug a biosimilar?
Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
How should side effects of the new checkpoint inhibitor drugs be managed?
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.
A widely prescribed pain/anti-inflammatory medication reduced the growth of neurofibromatosis type 2 tumors in mice and in cell cultures, suggesting that the drug could reduce tumor growth in some cancers.
US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.
Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.
Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.
The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
A month of treatment with the newest cancer drugs, based on those introduced in 2014, was 6 times more expensive at launch than cancer drugs introduced in 2000, after adjusting for inflation.
This fact sheet explains investigational drugs and the process by which cancer patients may obtain them.
Progression-free-survival was improved in all prespecified patient groups, including those with high-risk cytogenetic abnormalities.
Patient responses to the medication questions on the HCAHPS survey demonstrate improved understanding of their medications after implementation of an improved patient education process.
Recent survey data indicates that the majority of respondents held incorrect beliefs about both U.S. Food and Drug Administration (FDA) approval standards.
Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.
In a small group of women with mismatch repair (MMR) deficiency endometrial uterine cancer, survival was increased by pembrolizumab.
Access to specialty drugs is significantly reduced when insurers require patients to share the high costs of these drugs. Specialty drugs are often the only chance for patients with cancer to achieve long-term survival.
With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.
What is the new drug called Empliciti and how does it differ from other drugs used to treat multiple myeloma?
Oncology drug costs continue to rise, and the financial distress patients experience has led many to call for efforts to reduce oncology drug prices. Viable policy interventions will not be free and will involve tradeoffs, according to a team of experts.
Paclitaxel administered with carboplatin on a weekly basis is not associated with improved progression-free survival.
- Hypnosis and Its Use in Cancer Treatment
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- 3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma
- Lung Cancer Navigator App Aims to Help Patients Understand Disease
- Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Melanoma Incidence Still on the Rise in Parts of the United States
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|